Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 792

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Guidelines for the Management of Pediatric and Adult Tumor Lysis Syndrome: An Evidence-Based Review

Coiffier, Bertrand, Altman, Arnold, Pui, Ching-Hon, Younes, Anas, Cairo, Mitchell S. · 2008 · Journal of Clinical Oncology

Abstract

Purpose: Tumor lysis syndrome (TLS) has recently been subclassified into either laboratory TLS or clinical TLS, and a grading system has been established. Standardized guidelines, however, are needed to aid in the stratification of patients according to risk and to establish prophylaxis and treatment recommendations for patients at risk or with established TLS. Methods: A panel of experts in pediatric and adult hematologic malignancies and TLS was assembled to develop recommendations and guidelines for TLS based on clinical evidence and standards of care. A review of relevant literature was also used. Results: New guidelines are presented regarding the prevention and management of patients at risk of developing TLS. The best management of TLS is prevention. Prevention strategies include hydration and prophylactic rasburicase in high-risk patients, hydration plus allopurinol or rasburicase for intermediate-risk patients, and close monitoring for low-risk patients. Primary management of established TLS involves similar recommendations, with the addition of aggressive hydration and diuresis, plus allopurinol or rasburicase for hyperuricemia. Alkalinization is not recommended. Although guidelines for rasburicase use in adults are provided, this agent is currently only approved for use in pediatric patients in the United States. Conclusion: The potential severity of complications resulting from TLS requires measures for prevention in high-risk patients and prompts treatment in the event that symptoms arise. Recognition of risk factors, monitoring of at-risk patients, and appropriate interventions are the key to preventing or managing TLS. These guidelines should assist in the prevention of TLS and improve the management of patients with established TLS.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2007.15.0177

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 26 references

Research works printed but not linked: 27

  1. Van den Berghe G: Purine and pyrimidine metabolism between millennia: What has been accomplished, what has to be done? Adv Exp Med Biol 486:1,2000-4, · doi:10.1007/0-306-46843-3_1
  2. 10.3816/CLM.2002.s.011 · doi:10.3816/clm.2002.s.011
  3. 10.1016/0002-9343(93)90174-N · doi:10.1016/0002-9343(93)90174-n
  4. 10.1016/0002-9343(75)90597-5 · doi:10.1016/0002-9343(75)90597-5
  5. 10.1002/1097-0142(19900715)66:2<246::AID-CNCR2820660209>3.0.CO;2-B · doi:10.1002/1097-0142(19900715)66:2<246::aid-cncr2820660209>3.0.co;2-b
  6. 10.1002/1097-0142(19851101)56:9<2295::AID-CNCR2820560926>3.0.CO;2-X · doi:10.1002/1097-0142(19851101)56:9<2295::aid-cncr2820560926>3.0.co;2-x
  7. 10.1001/archinte.1987.00370020193063 · doi:10.1001/archinte.1987.00370020193063
  8. 10.1200/JCO.1998.16.7.2313 · doi:10.1200/jco.1998.16.7.2313
  9. 10.1038/sj.leu.2402847 · doi:10.1038/sj.leu.2402847
  10. 10.1056/NEJM196603032740902 · doi:10.1056/nejm196603032740902
  11. 10.1007/BF00860751 · doi:10.1007/bf00860751
  12. 10.1016/S0022-3476(86)80387-0 · doi:10.1016/s0022-3476(86)80387-0
  13. 10.1097/00005792-198105000-00005 · doi:10.1097/00005792-198105000-00005
  14. 10.1016/0006-2952(77)90191-5 · doi:10.1016/0006-2952(77)90191-5
  15. 10.1056/NEJM197008132830708 · doi:10.1056/nejm197008132830708
  16. 10.1053/shem.2001.20861 · doi:10.1053/shem.2001.20861
  17. Brogard JM, Coumaros D, Franckhauser J, et al: Enzymatic uricolysis: A study of the effect of a fungal urate-oxydase. Rev Eur Etud Clin Biol 17:890,1972-895, · doi:10.1088/0031-9155/17/6/097
  18. 10.1016/S0022-3476(82)80259-X · doi:10.1016/s0022-3476(82)80259-x
  19. 10.1053/shem.2001.27079 · doi:10.1053/shem.2001.27079
  20. 10.3816/CLM.2008.n.003 · doi:10.3816/clm.2008.n.003
  21. Annemans L, Moeremans K, Lamotte M, et al: Pan-European multicentre economic evaluation of recombinant urate oxidase (rasburicase) in prevention and treatment of hyperuricaemia and tumour lysis syndrome in haematological cancer patients. Support Care Cancer 11:249,2003-257, · doi:10.1007/s00520-002-0435-3
  22. 10.1182/blood-2004-03-0888 · doi:10.1182/blood-2004-03-0888
  23. 10.1053/sonc.2001.20747 · DOI
  24. 10.1080/08998280.2005.11928082 · doi:10.1080/08998280.2005.11928082
  25. Friedman EA: An introduction to phosphate binders for the treatment of hyperphosphatemia in patients with chronic kidney disease. Kidney Int Suppl S2,2005-S6, · doi:10.1016/s0085-2538(15)51226-x
  26. 10.1007/BF00866363 · doi:10.1007/bf00866363
  27. 10.1007/BF00857665 · doi:10.1007/bf00857665

Cited by

See all 792

Metadata

Authors
Coiffier, B., Altman, A., Pui, C.-H., Younes, A., & Cairo, M. S.
Venue
Journal of Clinical Oncology
Published
2008-06-01
Volume
26
Issue
16
Pages
2767-2778
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2141234027
Cited by
792
References
26
FWCI
37.01
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Guidelines for the Management of Pediatric and Adult Tumor Lysis Syndrome: An Evidence-Based Review. https://app.cochat.ai/papers/10.1200/jco.2007.15.0177
The paper
Coiffier, B., Altman, A., Pui, C.-H., Younes, A., & Cairo, M. S. (2008). Guidelines for the Management of Pediatric and Adult Tumor Lysis Syndrome: An Evidence-Based Review. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2007.15.0177

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.